September 30 (Mon) - October 2 (Wed), 2019

October 2 (Wed), 12:20-13:10, Rm. 300

ABL Bio Inc., is a Korean biotech, with market capitalization of about KRW 1,500 billion with 76 employees. Bispecific antibody (BsAb) is ABL Bio's main platform technology that enables to connect two different antibodies together, ensuing synergistic activity of the two antibodies. BsAb technologies are being heavily applied to the pipelines for oncology and neurodegenerative diseases that have unmet medical needs as well as high business opportunities.

ABL001 is the most advanced BsAb asset, targeting VEGF and DLL4. ABL Bio has strong portfolio of immune-oncology (I/O) with its bispecific platform. In spite of potent anti-tumor activities by antibody therapeutics of immune-checkpoint inhibitors or T-cell engagers, concerns about their severe toxicity and patient population with little response have been raised. ABL Bio expects bispecific antibodies in I/O will provide better therapeutic options for patients with low response to conventional immune-checkpoint inhibitors. ABL 301 is an α-synuclein (α-syn)-targeting BsAb for Parkinson's disease (PD) with maximized penetrance of blood-brain barrier (BBB) and therapeutic efficacy. ABL Bio plans to apply its BBB technology to other pipelines for neurodegenerative diseases, such as Alzheimer's disease.

ABL Bio will continue its effort to become a global innovator with its promise to make medicines for 'A Better Life'.